共 8 条
[1]
Ticagrelor: A Novel Reversible Oral Antiplatelet Agent[J] . James J. Nawarskas,Sara M. Clark.Cardiology in Review . 2011 (2)
[2]
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials[J] . Michelle L O’Donoghue,Eugene Braunwald,Elliott M Antman,Sabina A Murphy,Eric R Bates,Yoseph Rozenman,Alan D Michelson,Raymond W Hautvast,Peter N Ver Lee,Sandra L Close,Lei Shen,Jessica L Mega,Marc S Sabatine,Stephen D Wiviott.The Lancet . 2009 (9694)
[3]
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction （TRITON-TIMI 38）: double-blind, randomised controlled trial[J] . Gilles Montalescot,Stephen D Wiviott,Eugene Braunwald,Sabina A Murphy,C Michael Gibson,Carolyn H McCabe,Elliott M Antman.The Lancet . 2009 (9665)
[4]
Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: The Early Rapid ReversAl of Platelet ThromboSis with Intravenous Elinogrel before PCI to Optimize REperfusion in Acute Myocardial Infarction （ERASE MI） pilot trial[J] . Jeffrey S. Berger,Matthew T. Roe,C. Michael Gibson,Rakhi Kilaru,Cynthia L. Green,Laura Me
[5]
Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38[J] . Stephen D. Wiviott,Eugene Braunwald,Dominick J. Angiolillo,Simha Meisel,Anthony J. Dalby,Freek W.A. Verheugt,Shaun G. Goodman,Ramon Corbalan,Drew A. Purdy,Sabina A. Murphy,Carolyn H. McCabe,Elliott M. Antman.Circulation . 2008
[6]
Safety, Tolerability, and Initial Efficacy of AZD6140, the First Reversible Oral Adenosine Diphosphate Receptor Antagonist, Compared With Clopidogrel, in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome[J] . Journal of the American College of Cardiology . 2007 (19)
[7]
Preclinical and clinical studies with selective reversible direct P2Y12 antagonists
[J].
SEMINARS IN THROMBOSIS AND HEMOSTASIS,
2005, 31 (02)
:195-204
van Giezen, JJJ
;
Humphries, RG
.
[8]
Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Farid NA,Payne CD,Small DS,et al. Clinical Pharmacology and Therapeutics . 2007